SEC Comment Letter 0000000000-22-013682 to BioPlus Acquisition Corp. (CIK 0001856653)
BioPlus Acquisition Corp. (CIK 0001856653)
Date: Dec. 19, 2022 · CIK: 0001856653 · Accession: 0000000000-22-013682
AI Filing Summary & Sentiment
File numbers found in text: 001-41116
Letter
United States securities and exchange commission logo December 19, 2022 Ross Haghighat Chief Executive Officer and Chief Financial Officer BioPlus Acquisition Corp. 260 Madison Avenue, Suite 800 New York, NY 10026 Re:BioPlus Acquisition Corp. Form 10-K for the year ended December 31, 2021 File No. 001-41116 Dear Ross Haghighat: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for the year ended December 31, 2021 General 1.With a view toward disclosure, please tell us whether your sponsor is, is controlled by, or has substantial ties with a non-U.S. person. If so, please revise your disclosure in future filings to include disclosure that addresses how this fact could impact your ability to complete your initial business combination. For instance, discuss the risk to investors that you may not be able to complete an initial business combination with a U.S. target company should the transaction be subject to review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (CFIUS), or ultimately prohibited. Disclose that as a result, the pool of potential targets with which you could complete an initial business combination may be limited. Further, disclose that the time necessary for government review of the transaction or a decision to prohibit the transaction could prevent you from completing an initial business combination and require you to liquidate. Disclose the consequences of liquidation to investors, such as the losses of the investment opportunity in a target company, any price appreciation in the combined company, and the warrants, which would expire worthless. Please include an example of
FirstName LastNameRoss Haghighat Comapany NameBioPlus Acquisition Corp. December 19, 2022 Page 2 FirstName LastName Ross Haghighat BioPlus Acquisition Corp. December 19, 2022 Page 2 your intended disclosure in your response. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Eric McPhee at 202-551-3693 or Wilson Lee at 202-551-3468 if you have any questions. Sincerely, Division of Corporation Finance Office of Real Estate & Construction
Show Raw Text
United States securities and exchange commission logo
December 19, 2022
Ross Haghighat
Chief Executive Officer and Chief Financial Officer
BioPlus Acquisition Corp.
260 Madison Avenue, Suite 800
New York, NY 10026
Re:BioPlus Acquisition Corp.
Form 10-K for the year ended December 31, 2021
File No. 001-41116
Dear Ross Haghighat:
We have reviewed your filing and have the following comment. In our comment, we
may ask you to provide us with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-K for the year ended December 31, 2021
General
1.With a view toward disclosure, please tell us whether your sponsor is, is controlled by, or
has substantial ties with a non-U.S. person. If so, please revise your disclosure in future
filings to include disclosure that addresses how this fact could impact your ability to
complete your initial business combination. For instance, discuss the risk to investors that
you may not be able to complete an initial business combination with a U.S. target
company should the transaction be subject to review by a U.S. government entity, such as
the Committee on Foreign Investment in the United States (CFIUS), or ultimately
prohibited. Disclose that as a result, the pool of potential targets with which you could
complete an initial business combination may be limited. Further, disclose that the time
necessary for government review of the transaction or a decision to prohibit the
transaction could prevent you from completing an initial business combination and require
you to liquidate. Disclose the consequences of liquidation to investors, such as the losses
of the investment opportunity in a target company, any price appreciation in the combined
company, and the warrants, which would expire worthless. Please include an example of
FirstName LastNameRoss Haghighat
Comapany NameBioPlus Acquisition Corp.
December 19, 2022 Page 2
FirstName LastName
Ross Haghighat
BioPlus Acquisition Corp.
December 19, 2022
Page 2
your intended disclosure in your response.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Eric McPhee at 202-551-3693 or Wilson Lee at 202-551-3468 if you
have any questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction